Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Olanzapine - Eli Lilly and Company

Drug Profile

Olanzapine - Eli Lilly and Company

Alternative Names: LY 170053; LY-170052; Midax; Olanzapine controlled-release; Olanzapine LAI; Olanzapine long-acting; Olanzapine pamoate; Zypadhera; Zyprexa; Zyprexa Relprevv; Zyprexa Velotab; Zyprexa Zydis

Latest Information Update: 07 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Class Antidepressants; Antiemetics; Antimanics; Antipsychotics; Behavioural disorder therapies; Benzodiazepines; Mood stabilisers; Oxazepines; Small molecules; Thiazepines
  • Mechanism of Action Dopamine D1 receptor antagonists; Dopamine D2 receptor antagonists; Serotonin 5-HT2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Aggression; Bipolar depression; Bipolar disorders; Manic episodes; Schizophrenia
  • No development reported Anorexia nervosa; Huntington's disease; Major depressive disorder; Personality disorders

Most Recent Events

  • 07 Jan 2024 NDR batch #30: No updates; kept NDR as it is as trial completed in 2016 and Dev line is NDR from 2021 but as drug was in phase III development and no any source for discontinuation found hence not marked as discontinued mail sent to the company for confirmation
  • 23 Jul 2023 Cheplapharm acquires worldwide commercial rights to olanzapine from Eli Lilly
  • 08 Apr 2021 No development reported - Phase-III for Major depressive disorder (Combination therapy, Treatment-resistant) in China (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top